E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
acute myocardial infarction |
infarto agudo de miocardio |
|
E.1.1.1 | Medical condition in easily understood language |
acute myocardial infarction |
infarto agudo de miocardio |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000891 |
E.1.2 | Term | Acute myocardial infarction |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the study is to determine whether Cyclosporine A, administered immediately prior to PCI reperfusion improves clinical outcomes in AMI patients |
El objetivo del presente estudio es determinar si la ciclosporina A puede mejorar el resultado clínico de los pacientes con IAMEST. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are: - to determine whether cyclosporine A, administered immediately prior to PCI reperfusion has an effect on: 1) Mortality events following AMI (at 30 days and 1 year) 2) Cardiac and vascular events following AMI 3) Cardiac prognostic factors
- to describe the tolerance of medicinal investigational products. |
Determinar si la administración intracoronaria de ciclosporina A antes de la reperfusión tiene efecto sobre 1) la mortalidad post IAM (a los 30 días y 1 año) 2) eventos cardíacos y vasculares post IAM 3) factores de prognóstico cardíaco. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The principal investigators of each of these sub-studies will have to develop a specific sub-study protocol and submit it first to approval to the Steering Committee, and afterwards to approval of local authorities and the IEC (independent ethic committee). The main sub-studies that were already submitted and approved by the Steering Committee are listed below:
1/ study of adiponectin (Principal Investigator: Dr. Marc Claeys, belgium) Adiponectin will be measured in an estimated number of 256 patients in the control group in order to assess relation between adiponectin levels and occurrence of reperfusion injury. Comparisons will be made between an estimated 64 patients in the low quartile of adiponectin vs. the others, as well as interaction with the study treatment. This sub-study will be linked to the bio-bank.
2/ MRI substudy Assessment of the effect of cyclosporine treatment of infarct size and microvascular obstruction (MVO: no reflow) by MRI.
3/ cyclophilin D (Principal Investigator: Dr. Michel Ovize, France) Objective: to determine whether circulating cypD may be a marker that may predict infarct size. This sub-study will be linked to the bio-bank
4/ genetic association study Centralised genetic samples will be collected in an ancillary study. |
|
E.3 | Principal inclusion criteria |
1. All (male and female) patients, aged over 18, without any legal protection measure 2. Having a health coverage 3. Presenting within 12 hours of the onset of chest pain, 4. Who have ST segment elevation > 0.2 mV in two contiguous leads, 5. For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI). And (further inclusion criteria to be confirmed by the admission coronary-angiography) 6. The culprit coronary artery has to be the LAD 7. The LAD artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography. 8. Preliminary oral informed consent followed by signed informed consent as soon as possible. Patients undergoing either primary PCI or rescue PCI are eligible for the study. Patients with previous AMI, PCI or coronary artery bypass surgery (CABG) are eligible for the study. |
Pacientes (mujeres y hombres), mayores de 18 años, con cobertura médica, que se presenten en las primeras 12 horas tras el inicio de dolor torácico y con elevación de ST > 0.2 mV en dos derivaciones consecutivas y que sean tratados con angioplastia. La arteria coronaria responsable debe ser la descendente anterior (DA) y debe estar ocluida (TIMI 0-1) en el momento de realizar la primera inyección angiográfica. Tanto los pacientes que reciban angioplastia primaria como de rescate se pueden incluir en el estudio |
|
E.4 | Principal exclusion criteria |
1. Patients with loss of consciousness or confused 2. Patients with cardiogenic shock 3. Patients with the left circumflex or the right coronary artery (RCA) as the culprit artery, or with evidence of coronary collaterals to the risk region 4. Patients with an opened (TIMI > 1) LAD coronary artery at admission on initial (admission) coronary angiography 5. Patients with - known hypersensitivity to cyclosporine - known renal insufficiency (either known creatinin clearance < 30 ml/min/1.73m² or current medical care for severe renal insufficiency) - known liver insufficiency - uncontrolled (treated or untreated) hypertension (> 180/110 mmHg) 6. Patients treated with - any compound containing Hypericum perforatum (St.-John?s-worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine - an active treatment that might modify blood concentration of Cyclosporine (diltiazem, vérapamil?) 7. Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis). 8. Patients with any disorder associated with immunological dysfunction more recently than 6 months prior to presentation - cancer, lymphoma - known positive serology for HIV, or hepatitis |
Pacientes con pérdida de conocimiento o confusos. Pacientes en situación de shock cardiogénico; pacients cuya arteria responsable sea Circunfleja (CF) o derecha (CD) o que presenten evidencia de circulación colateral en la zona de riesgo, arteria responsable abierta (TIMI > 1 en DA en la primera inyección angiográfica); pacientes con hipersensibilidad conocida a la Ciclosporina A, huevo, frutos secos, proteínas de soja, o con insuficiencia renal conocida (aclaramiento de creatinina documentado previamente < 30 ml/min/1.73m² o que reciben atención médica por insuficiencia renal severa, insuficiencia hepática conocida, hipertensión no controlado (> 180/110 mmHg), tratada o sin tratar; pacientes tratados con cualquier compuesto que contenga Hypericum perforatum ( Hierba de San Juan ) o Estiripentol o Aliskiren o Bosentan o Rosuvastatina o con un tratamiento activo que puede modificar la concentración en sangre de Ciclosporina A ( diltiazem , verapamilo?); mujeres embarazadas o en edad fértil que no usen métodos anticonceptivos; Pacientes con cualquier alteración del sistema inmunitario en los 6 meses previos al inicio del estudio: cáncer, linfoma, serología positiva para VIH o hepatitis. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Combined incidence of [total mortality; hospitalization for heart failure; LV remodelling (increase of LV end-diastolic volume >15%)] at one year post-AMI |
Incidencia combinada de [mortalidad total, hospitalización por insuficiencia cardíaca, remodelado ventricular (aumento del volumen telediastólico vetricular izquierdo >15%)] al cabo de año del IAMEST. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 year post AMI |
un año post-IAM |
|
E.5.2 | Secondary end point(s) |
- Mortality events : 1. All causes of mortality 2. Cardiovascular deaths
- Cardiac and vascular events : 1. Heart failure: 1) in-hospital worsening of heart failure after reperfusion, 2) re-hospitalization for: a) worsening of a heart failure existing at admission, b) appearance of ?new? heart failure 2. Myocardial infarction 3. Unstable angina 4. Stroke 5. LV remodelling
- Cardiac prognostic factors : 1. Infarct size: peak Troponin (T or I) 2. LV function at one year 3. Microvascular obstruction (no reflow)
- Tolerance to medicinal investigational products |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- 30 days and 1 year for mortality events - 1 year for other end points |
Valorados a los 12 meses. 1) mortalidad total, 2) mortalidad de causa cardiovascular, -Eventos cardíacos y vasculares [empeoramiento de la insuficiencia cardiaca después de la reperfusión durante el ingreso, o re-hospitalización por: 1) empeoramiento de la insuficiencia cardiaca ya presente en el momento del ingreso, 2) nueva aparición de la insuficiencia cardiaca] 2)infarto de miocardio, 3)angina inestable, 4)Accidente vascular cerebral (AVC) 5)remodelado ventricular Factores de interés pronóstico cardíaco: 1. Tamaño del infarto: Pico de troponinas (To I) 2. Función Ventrículo Izquierdo a un año 3. Obstrucción microvascular (No reflow) Tolerancia a los productos medicos investigados |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 60 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient's last visit |
última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |